ArticleEBioMedicine2018
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Xia Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
37 papers cite it
this papercites it